Sponsors |Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer – October 1st, 8th, 15th & 22nd, 2020

miR Scientific, LLC is a precision bioscience company committed to improving public health by transforming cancer management globally. The Company has developed the miR Scientific Sentinel Prostate Assay that offers non-invasive liquid biopsy urine tests that accurately detect and precisely classify prostate cancer at the molecular level with industry-leading Sensitivity and Specificity. Our molecular diagnostic capabilities approach cancer detection, classification, and monitoring through a new lens with advanced sncRNA interrogation techniques, a proprietary scoring algorithm, and innovative clinical decision support tools.

To learn more, please visit: www.mirscientific.com

Progenics Pharmaceuticals, Inc., a subsidiary of Lantheus Holdings, Inc., is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agent for prostate cancer (PyL™); and imaging analysis technology (aBSI and PSMA AI).

To learn more, please visit: www.progenics.com and www.lantheus.com

Telix Pharmaceuticals (US) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

To learn more, please visit: www.telixpharma.com/

To learn more, please visit: www.adacap.com

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. Fluciclovine F 18 has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology. The company’s pipeline includes innovative Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging.

To learn more, please visit: www.blueearthdiagnostics.com

KOELIS was founded with the vision to offer the most confident and accurate prostate cancer diagnosis to their patients, avoiding any under or overtreatment and preserving quality of life.

With the support of forward-thinking partners, investors, and hospitals, our vision is rapidly becoming a reality.

Today, the KOELIS Trinity® platform is recognized as a gold standard for MRI fusion Prostate biopsy, providing accuracy and reliability at every step of the process, from biopsy and active surveillance to treatment and follow-up.

Over 300 hospitals in more than 25 countries have already given 300,000 men access to more precise prostate cancer diagnosis thanks to our technologies.

To learn more, please visit: www.Koelis.com

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best scientific breakthroughs into clinical application for patients across a diverse array of solid tumors and hematologic cancers. Today, we have 10 approved oncology medicines and 14 assets currently in clinical development. By maximizing our internal scientific resources and collaborating with other companies, government and academic institutions, as well as patients and non-profit and professional organizations, we are bringing together the brightest and most enterprising minds to take on the toughest cancers. Together we can accelerate breakthrough treatments to patients around the world and work to redefine life with cancer.

To learn more, please visit: www.Pfizer.com

Exact Imaging’s ExactVu™ 29 MHz micro-ultrasound platform provides a 300% improvement in resolution over conventional ultrasound enabling real-time targeted prostate biopsies.  It is simple, affordable, and an extension of the current urological workflow. For the minority of cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the same platform – – and is guided by the real-time 70 micron resolution of the ExactVu system.

To learn more, please visit: http://www.exactimaging.com/

_ _ _

A global leader in therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using high intensity focused ultrasound (HIFU) technology for non-invasive ablation of prostate tissue, micro-ultrasound technology for diagnosis and targeted biopsies for prostate cancer, and extracorporeal shockwave lithotripsy (ESWL) for treatment of urinary stones. Combining Exact Imaging’s ExactVu™ device with Focal One®, EDAP TMS is the only company offering a complete solution from precision diagnostics to non-invasive ablation for Prostate Cancer patients.

To learn more, please visit: www.EDAP-tms.com

ADVANCING THE FIGHT AGAINST CANCER

In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicines for cancer.

We seek to develop targeted therapies to better serve patients and ensure the right drug gets to the right patient.

To learn more, please visit: www.clovisoncology.com

HealthTronics: Partner with healthcare organizations and clinicians to efficiently deliver high quality patient care by extending access to exceptional medical technologies and services.

To learn more, please visit: www.healthtronics.com

Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

To learn more, please visit: www.sanofigenzyme.com